Aveo could lose Fotivda's EU approval if August analysis confirms negative OS trend

EMA's CHMP will consider regulatory action should an interim overall survival analysis of Fotivda tivozanib, planned for August, confirms the negative OS

Read the full 221 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE